Astellas 2012 First Quarter Lipitor Sales Down 30%
This article was originally published in PharmAsia News
Astellas announced its first quarter results, and domestic sales of Lipitor, which Astellas produces for Pfizer in Japan, decreased 32.8% as prices of the drug were decreased by 11% when it launched as a generic drug in November 2011.
You may also be interested in...
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.